| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:14757517 | IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:16203236 | IVR | 1 mg/kg/day | 1 mg/kg/day | Accelerated onset of diabetes | Metabolic endocrine-mediated perturbations |
| PMID:18674613 | IVR | 3 mg/kg | 3 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 3 mg/kg | 3 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:19165396 | IVR | 6 mg/kg | 6 mg/kg | Decreased arginine vasopressin levels | Neurological endocrine-mediated perturbations |
| IVR | 6 mg/kg | 6 mg/kg | Increased oxytocin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Decreased arginine vasopressin levels | Neurological endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Increased oxytocin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Increased oxytocin levels | Reproductive endocrine-mediated perturbations | |
| PMID:19190125 | IVR | 480 mg/kg/day | 480 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 480 mg/kg/day | 480 mg/kg/day | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 960 mg/kg/day | 960 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 960 mg/kg/day | 960 mg/kg/day | Induce apoptosis of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg/day | - | No significant effects observed | - | |
| PMID:21453761 | IVR | 1 mg/kg | 1 mg/kg | Increased levels of norepinephrine | Neurological endocrine-mediated perturbations |
| PMID:23686008 | IVR | 1 mg/kg/day | 1 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| PMID:26518068 | IVR | 1 mg/kg/day | 1 mg/kg/day | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| PMID:31826669 | IVR | 10 mg/kg | 10 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increase in T3 levels | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.